925216-62-2

Basic information

• Product Name: 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine
• Synonyms: 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine
• CAS NO: 925216-62-2
• Molecular Weight: 453.544
• Mol File: 925216-62-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine(925216-62-2)
• EPA Substance Registry System: 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine(925216-62-2)

Safety Data

• Hazardous Substances Data: 925216-62-2(Hazardous Substances Data)

Upstream product

• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 75821-80-6 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine 
• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 100-36-7 N,N-diethylethylenediamine 
• 911-65-9 etonitazene 
• 55154-71-7 N-[2-{(2-(diethylamino)ethyl)amino}-5-nitrophenyl]-2-(4-ethoxyphenyl)acetamide 
• 56223-91-7 N’-(2,4-dinitrophenyl)-N,N-diethylethane-1,2-diamine 
• 5099-39-8 N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine 

Relevant articles and documents

NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity

A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.